<DOC>
	<DOC>NCT02964455</DOC>
	<brief_summary>The phase I study is to determine the maximum tolerated dose and dose limiting toxicity of docetaxel and nedaplatin prescribed twice weekly in combination with concurrent chest radiotherapy in patients with locally advanced esophageal squamous cell carcinoma.</brief_summary>
	<brief_title>Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<criteria>Histologically confirmed esophageal squamous cell carcinoma Inoperable stage IIIVa (UICC 2002; sixth edition), confirmed by contrast enhanced computed tomography,endoscopic ultrasonography, barium esophagram, emission computed tomography and/or positron emission tomography/computed tomography. Eastern Cooperative Oncology Group (ECOG) performance status 12 Estimated life expectancy of at least 12 weeks Charlson comorbidity index≤4 Adequate bone marrow function: white blood cells grade 0 or 1,absolute neutrophils grade 0 or 1, platelets grade 0, haemoglobin grade 0 or 1 Adequate renal function: creatinine grade 0 or 1 Adequate liver function: serum bilirubin grade 0 or 1, alanine aminotransferase and aspartate aminotransferase &lt;2 times of the upper normal limit Weight loss≤15% during 6 months prior to diagnosis Forced expiratory volume second≥1L Prior history of malignancy, except for nonmelanoma skin carcinoma or cervical carcinoma in situ Previous antitumor therapy, including surgery, chemotherapy or radiotherapy Contraindication for chemotherapy or radiotherapy Malignant pleural or pericardial effusion Women in pregnancy or lactation period Women who has the probability of pregnancy without contraception Weight loss≥15% during 3 months prior to diagnosis In other clinical trials within 30 days Addicted in drugs or alcohol, AIDS patients Uncontrollable seizure or psychotic patients without selfcontrol ability Severe allergy or idiosyncrasy Not suitable for this study judged by researchers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Esophageal squamous cell carcinoma</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Nedaplatin</keyword>
	<keyword>Twice weekly</keyword>
</DOC>